🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-522335-34-00
Authorised Phase I

(22597) A study to learn about how safe nitroglycerin is and how it affects the body when taken along with nurandociguat in people with coronary artery disease.

2025-522335-34-00 · tracked via the Priya Life Science EU tracker
Sponsor
Bayer AG
Sponsor type
Pharmaceutical company
Therapeutic area
Cardiovascular Diseases
Decision date
22/01/2026
Enrollment target
36
Sites
Germany, Bulgaria

Condition studied

Chronic kidney disease, Coronary artery disease

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-522335-34-00 on CTIS ↗ ← All trials in the EU